Pharmacotherapy of Irritability in Pervasive Developmental Disorders

Child and Adolescent Psychiatric Clinics of North America

Volumn 17, Issue 4, 2008, Pages 739-752

  Stigler, Kimberly A ^a   McDougle, Christopher J ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLONIDINE; CLOZAPINE; ETIRACETAM; FLUVOXAMINE; GUANFACINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; MOOD STABILIZER; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; TOPIRAMATE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ADOLESCENT; AGGRESSION; AGITATION; AGRANULOCYTOSIS; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGER; AUTISM; AUTOMUTILATION; BEHAVIOR DISORDER; BEHAVIORAL ACTIVATION; CHILD; CLINICAL TRIAL; CONSTIPATION; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; ENURESIS; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; FATIGUE; FOOD AND DRUG ADMINISTRATION; HAIR LOSS; HUMAN; HYPERACTIVITY; HYPERAMMONEMIA; HYPERSALIVATION; HYPOTENSION; INCREASED APPETITE; INSOMNIA; IRRITABILITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; QT PROLONGATION; RASH; REVIEW; SEDATION; SEIZURE; SEIZURE THRESHOLD; SIDE EFFECT; SOMNOLENCE; SYMPTOM; TARDIVE DYSKINESIA; WEIGHT CHANGE; WEIGHT GAIN;

ADOLESCENT; AGGRESSION; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; AUTISTIC DISORDER; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; CLONIDINE; HUMANS; IRRITABLE MOOD; PSYCHOTROPIC DRUGS; SELF-INJURIOUS BEHAVIOR;

EID: 50449087749     PISSN: 10564993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chc.2008.06.002     Document Type: Review

References (51)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th edition, text revision (DSM-IV-TR) (2000), American Psychiatric Publishing, Washington, DC
2. McDougle C.J., Posey D.J., and Stigler K.A. Pharmacological treatments. In: Moldin S.O., and Rubenstein J.L.R. (Eds). Understanding autism: from basic neuroscience to treatment (2006), CRC Press, Boca Raton (FL) 417-442
3. Campbell M., Geller B., and Cohen I.L. Current status of drug research and treatment with autistic children. J Pediatr Psychol 2 (1977) 153-161
4. Campbell M., Anderson L.T., Meier M., et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry 17 (1978) 640-655
5. Fish B. Children's Psychiatric Rating Scale (scoring). Psychopharmacol Bull 21 (1985) 753-764
6. Cohen I.L., Campbell M., Posner D., et al. Behavioral effects of haloperidol in young autistic children. J Am Acad Child Adolesc Psychiatry 19 (1980) 665-677
7. Anderson L.T., Campbell M., Grega D.M., et al. Haloperidol in the treatment of infantile autism: effects on learning and behavioral symptoms. Am J Psychiatry 141 (1984) 1195-1202
8. Anderson L.T., Campbell M., Adams P., et al. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord 19 (1989) 227-239
9. Perry R., Campbell M., Adams P., et al. Long-term efficacy of haloperidol in autistic children: continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry 28 (1989) 87-92
10. Campbell M., Armenteros J.L., Malone R.P., et al. Neuroleptic-related dyskinesias in autistic children: a prospective, longitudinal study. J Am Acad Child Adolesc Psychiatry 36 (1997) 835-843
11. Pierre J.M. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf 28 (2005) 191-208
12. Zuddas A., Ledda M.G., Fratta A., et al. Clinical effects of clozapine on autistic disorder. Am J Psychiatry 153 5 (1996) 738
13. Chen N.C., Bedair H.S., McKay B., et al. Clozapine in the treatment of aggression in an adolescent with autistic disorder. J Clin Psychiatry 62 6 (2001) 479-480
14. Gobbi G., and Pulvirenti L. Long-term treatment with clozapine in an adult with autistic disorder accompanied by aggressive behavior. J Psychiatry Neurosci 26 (2001) 340-341
15. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. N Engl J Med 347 (2002) 314-321
16. Aman M.G., Singh N.N., Stewart A.W., et al. The aberrant behavior checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Defic 5 (1985) 485-491
17. McDougle C.J., Scahill L., Aman M.G., et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the Research Units on Pediatric Psychopharmacology. Am J Psychiatry 162 (2005) 1142-1148
18. Freeman B.J., Ritvo E.R., Yakota A., et al. A scale for rating symptoms of patients with the syndrome of autism in real life settings. J Am Acad Child Adolesc Psychiatry 25 (1986) 130-136
19. Scahill L., Riddle M.A., McSwiggin-Hardin M., et al. Children's Yale-Brown Obsessive Compulsive Scale: reliability and validity. J Am Acad Child Adolesc Psychiatry 36 (1997) 844-852
20. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 162 (2005) 1361-1369
21. Troost P.W., Lahuis B.E., Steenhuis M.P., et al. Long term effects of risperidone in children with autism spectrum disorders: a placebo discontinuation study. J Am Acad Child Adolesc Psychiatry 44 (2005) 1137-1144
22. Shea S., Turgay A., Carrol A., et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics 114 (2004) e634-e641
23. Schopler E., Reichler R.J., DeVellis R.F., et al. Toward objective classification of childhood autism: childhood autism rating scale (CARS). J Autism Dev Disord 10 (1980) 91-103
24. Miral S., Gencer O., Inal-Emiroglu F.N., et al. Risperidone versus haloperidol in children and adolescents with AD: a randomized, controlled, double-blind trial. Eur Child Adolesc Psychiatry 17 (2008) 1-8
25. Nagaraj R., Singhi P., and Malhi P. Risperidone in children with autism: randomized, placebo-controlled, double-blind study. J Child Neurol 21 (2006) 450-455
26. Luby J., Mrakotsky C., Stalets M.M., et al. Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. J Child Adolesc Psychopharmacol 16 (2006) 575-587
27. Potenza M.N., Holmes J.P., Kanes S.J., et al. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol 19 (1999) 37-44
28. Malone R.P., Cate J., Sheikh R.M., et al. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry 40 (2001) 887-894
29. Kemner C., Willemsen-Swinkels S.H., de Jonge M., et al. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol 22 (2002) 455-460
30. Hollander E., Wasserman S., Swanson E.N., et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol 16 (2006) 541-548
31. Martin A., Koenig K., Scahill L., et al. Open-label quetiapine in the treatment of children and adolescents with autistic disorder. J Child Adolesc Psychopharmacol 9 (1999) 99-107
32. Findling R.L., McNamara N.K., Gracious B.L., et al. Quetiapine in nine youths with autistic disorder. J Child Adolesc Psychopharmacol 14 (2004) 287-294
33. Corson A.H., Barkenbus J.E., Posey D.J., et al. A retrospective analysis of quetiapine in the treatment of pervasive developmental disorders. J Clin Psychiatry 65 (2004) 1531-1536
34. Hardan A.Y., Jou R.J., and Handen B.L. Retrospective study of quetiapine in children and adolescents with pervasive developmental disorders. J Autism Dev Disord 35 (2005) 387-391
35. McDougle C.J., Kem D.L., and Posey D.J. Case series: use of ziprasidone for maladaptive symptoms in youths with autism. J Am Acad Child Adolesc Psychiatry 41 (2002) 921-927
36. Cohen S.A., Fitzgerald B.J., Khan S.R., et al. The effect of a switch to ziprasidone in an adult population with autistic disorder: chart review of naturalistic, open-label treatment. J Clin Psychiatry 65 (2004) 110-113
37. Malone R.P., Delaney M.A., Hyman S.B., et al. Ziprasidone in adolescents with autism: an open-label pilot study. J Am Acad Child Adolesc Psychiatry 17 6 (2007) 779-790
38. Stigler K.A., Posey D.J., and McDougle C.J. Case report: aripiprazole for maladaptive behavior in pervasive developmental disorder. J Child Adolesc Psychopharmacol 14 (2004) 455-463
39. Valicenti-McDermott M.R., and Demb H. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities. J Child Adolesc Psychopharmacol 16 (2006) 549-560
40. Stigler K.A., Diener J.T., Kohn A.E., et al. Aripiprazole in Asperger's disorder and pervasive developmental disorder not otherwise specified: a 14-week prospective, open-label study. Program No. 35, Abstract Viewer (2007), American College of Neuropsychopharmacology, Boca Raton (FL)
41. Jaselskis C.A., Cook E.H., Fletcher K.E., et al. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12 (1992) 322-327
42. Fankhauser M.P., Karumanchi V.C., German M.L., et al. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry 53 3 (1992) 77-82
43. Posey D.J., Decker J., Sasher T.M., et al. Guanfacine treatment of hyperactivity and inattention in autism: a retrospective analysis of 80 cases. J Child Adolesc Psychopharmacol 14 (2004) 233-241
44. Epperson C.N., McDougle C.J., Anand A., et al. Lithium augmentation of fluvoxamine in autistic disorder: a case report. J Child Adolesc Psychopharmacol 4 (1994) 201-207
45. Hollander E., Dolgoff-Kaspar R., Cartwright C., et al. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry 62 7 (2001) 530-534
46. Hellings J.A., Weckbaugh M., Nickel E.J., et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. J Child Adolesc Psychopharmacol 15 4 (2005) 682-692
47. Uvebrant P., and Bauzine R. Intractable epilepsy in children: the efficacy of lamotrigine treatment, including non-seizure-related benefits. Neuropediatrics 25 (1994) 284-289
48. Belsito K.M., Law P.A., Kirk K.S., et al. Lamotrigine therapy for autistic disorder: a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 31 2 (2001) 175-181
49. Mazzone L., and Ruta L. Topiramate in children with autistic spectrum disorders. Brain Dev 28 10 (2006) 668
50. Rugino T.A., and Samsock T.C. Levetiracetam in autistic children: an open-label study. J Dev Behav Pediatr. 23 4 (2002) 225-230
51. Wasserman S., Iyengar R., Chaplin W.F., et al. Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. Int Clin Psychopharmacol 21 6 (2006) 363-367